Dear editor
We have with interest read the letter to the editor by Dr Ajay Malhotra and colleagues regarding our paper: ''Non-aneurysmal subarachnoid hemorrhage: When is a second angiography indicated?'' 1 We would like to take the opportunity to address the concerns raised.
Perimesencephalic subarachnoid hemorrhage (PMSAH) is a diagnosis of exclusion-meaning that all other possible causes must be carefully investigated and ruled out. Although PMSAH corresponds well with a normal computed tomography angiography (CTA) in most cases, a similar bleeding pattern has been reported in patients with a ruptured aneurysm of the posterior circulation. 2, 3 In addition, aneurysms with a diameter smaller than 3 mm (so-called ''baby'' aneurysms) can be missed by CTA examination in up to 9% of cases. 4 In the meta-analysis by Kalra et al., 5 an aneurysm in 8 out of 1031 patients (0.78%) was detected on follow-up imaging. Definition of PMSAH was not consistent throughout the included studies in the meta-analysis. This raises the question whether the reported estimate would have been the same if studies with the questionably defined PMSAH were excluded, as also stated by the authors in their discussion. Another meta-analysis from 2016 (majority of included studies from 2012 and 2013) reported an aneurysm detection rate of 1.6% in patients with a bleeding pattern similar to PMSAH who underwent a follow-up DSA after an initial negative DSA.
6 These results along with previous similar studies therefore have some implications, and thus, may be less applicable to clinical practice, as the clinicians are often obligated to find the etiology of subarachnoid hemorrhage. We believe that CTA at this point in time is still inadequate as a gold standard despite the fact that some clinicians are comfortable with this as a sole diagnostic approach. Although it is suggested to skip the DSA following a negative CTA, 5 there is still insufficient evidence to suggest that CTA alone is adequate in all centers. 4 Therefore, at least one DSA should be regarded as a gold standard in the case of PMSAH, preferably at the time of admission. A second DSA in such patients, on the other hand, is generally unnecessary, as also recommended by the authors in the meta-analysis. Finally, we retrospectively reviewed the case of the rebleeding after non-PMSAH. Both DSAs were performed by the same experienced neuroradiologist; the amount of contrast for each run was not recorded but the total amount of contrast used for the second DSA was greater (85 ml versus 55 ml) and no 3D-rotational spin was performed during the first DSA. However, having reviewed both DSAs, both were adequately performed, and having seen the various runs from both, the area where the aneurysm was located on the second DSA was well visualized on the first DSA, and the aneurysm was very easily seen on the second DSA. We therefore do not believe that it was missed on the initial DSA due to a technically insufficient examination.
